Description
Operator of a drug development company intended to carry out R&D on gene therapy technology targeting mainly neurodegenerative diseases. The company specializes in developing gene therapies for refractory diseases primarily focusing on Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease, enabling patients to get therapies while suffering from refractory diseases.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Later Stage VC | 24-Jun-2020 | Completed | Pre-Clinical Trials | |||
2. Later Stage VC | 24-Dec-2019 | Completed | Pre-Clinical Trials | |||
1. Secondary Transaction - Private | 19-Feb-2016 | $163K | 00000 | Completed | Pre-Clinical Trials |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210292790-A1 | Method for enhancing gene expression using aav vector | Pending | 30-Jul-2018 | 0000000000 | |
JP-WO2020026968-A1 | Method of enhancing gene expression by aav vector | Pending | 30-Jul-2018 | 000000000 | |
EP-3831949-A1 | Method for enhancing gene expression by aav vector | Pending | 30-Jul-2018 | C12N15/86 |
Name | Representing | Role | Since |
---|---|---|---|
Masako Kawase Ph.D | Gene Therapy Research Institution | Board Member | 000 0000 |
Shin-ichi Muramatsu Ph.D | Gene Therapy Research Institution | Chief Revenue Officer & Board Member | 000 0000 |
Shunta Nojiri | Gene Therapy Research Institution | Chief Financial Officer & Board Member | 000 0000 |
Takashi Nishibori | Gene Therapy Research Institution | Board Member | 000 0000 |
Toshihiko Sato MD | Gene Therapy Research Institution | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Alfresa | Corporation | Minority | 000 0000 | 000000 0 | |
Medical Incubator Japan | Venture Capital | Minority | 000 0000 | 000000 0 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000-0000000 | 02-Aug-2017 | 00000 0000 | Biotechnology | 000000000 |